Laura and Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health is a clinical research site located in New York, New York, United States 10016.

Crixeo Health Trust Score: 73/100 (FAIR). This profile has not yet been claimed by the site owner.

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health has participated in 8 clinical trials with 4 currently active.

Therapeutic areas: Melanoma, Cutaneous Malignant, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer.

Sponsors: Immatics US, Inc., EMD Serono Research & Development Institute, Inc., Dizal Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 73/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Laura and Isaac Perlmutter Cancer Center at NYU Langone Health?

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health has a Crixeo Trust Score of 73/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Laura and Isaac Perlmutter Cancer Center at NYU Langone Health conducted?

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health has 8 clinical trials on record, with 4 currently active. Their work covers Melanoma, Cutaneous Malignant, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer.

Is Laura and Isaac Perlmutter Cancer Center at NYU Langone Health accredited by Crixeo Health?

Yes — Laura and Isaac Perlmutter Cancer Center at NYU Langone Health holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Laura and Isaac Perlmutter Cancer Center at NYU Langone Health?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.